Role of renin-angiotensin system blockade in patients with diabetes mellitus.

Full Abstract

The investigators review the evidence of the potential role of renin-angiotensin system (RAS) blockers in delaying or preventing the onset and progression of diabetes mellitus (DM) and cardiovascular disease and the suggested mechanisms by which these agents exert their favorable metabolic and cardiovascular effects. Data from clinical trials suggest that RAS blockade not only reduces cardiovascular risk in patients with DM but also may prevent or delay DM onset in at-risk subjects. These observations set the stage for further studies evaluating the risk for developing DM as a primary end point: the Diabetes Reduction Approaches With Ramipril And Rosiglitazone Medications (DREAM) trial, in which ramipril significantly increased regression to normoglycemia (although it did not reduce the primary end point of new-onset DM or death), and the ongoing Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, the only DM prevention trial also powered to evaluate whether a reduced risk for DM is associated with a reduction in cardiovascular disease events. In conclusion, overwhelming evidence suggests that the RAS plays an important role in the pathogenesis of DM and its associated cardiovascular risks.

Author information

Author/s: Braga, Manoela F B (MF); Leiter, Lawrence A (LA);

Affiliation: Cardiometabolic Risk Initiative, St. Michael's Hospital, University of Toronto, Toronto, Ontario Canada.

Journal and publication information

Publication Type: Journal Article; Review

Journal: The American journal of cardiology (Am J Cardiol), published in United States. (Language: eng)

Reference: 2009-Sep; vol 104 (issue 6) : pp 835-9

Dates: Created 2009/09/07; Completed 2009/09/25;

PMID: 19733720, status: MEDLINE (last retrieval date: 9/25/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Ramipril - pharmacology; therapeutic use
Renin-Angiotensin System - drug effects; physiology
Tetrazoles - pharmacology; therapeutic use
Thiazolidinediones - pharmacology; therapeutic use
Valine - analogs & derivatives; pharmacology; therapeutic use
Vasodilation - physiology
Ventricular Function - physiology

Associated Chemicals: Angiotensin II Type 1 Receptor Blockers (0) ; Angiotensin-Converting Enzyme Inhibitors (0) ; Tetrazoles (0) ; Thiazolidinediones (0) ; rosiglitazone (122320-73-4) ; valsartan (137862-53-4) ; Valine (7004-03-7) ; Ramipril (87333-19-5)

These are the highest related articles currently in the database: